Cytokinetics Opens BENEFIT-ALS, A 400 Patient, Phase IIb Clinical…

BENEFIT-ALS Will Evaluate Longer Term Effects of Novel Skeletal Muscle Activator
and Represents a Key Step Forward Towards Potential Registration

(PRWeb October 29, 2012)

Read the full story at http://www.prweb.com/releases/2012/10/prweb10069735.htm

Click here for reuse options!
Copyright 2012 Biotechblog

Comments are closed.

%d bloggers like this: